SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
NCT07551635
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
FHD-286
Sponsor
Dana-Farber Cancer Institute
Collaborators
[object Object]